A detailed history of Telemus Capital, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Telemus Capital, LLC holds 19,589 shares of GILD stock, worth $1.85 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
19,589
Previous 17,801 10.04%
Holding current value
$1.85 Million
Previous $1.33 Million 18.89%
% of portfolio
0.13%
Previous 0.12%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 01, 2024

BUY
$73.27 - $83.09 $131,006 - $148,564
1,788 Added 10.04%
19,589 $1.59 Million
Q3 2023

Oct 25, 2023

BUY
$73.94 - $80.67 $1.04 Million - $1.14 Million
14,088 Added 379.42%
17,801 $1.33 Million
Q2 2023

Jul 10, 2023

BUY
$76.01 - $86.7 $88,551 - $101,005
1,165 Added 45.72%
3,713 $286,000
Q1 2023

Apr 11, 2023

BUY
$77.31 - $88.08 $196,985 - $224,427
2,548 New
2,548 $211,000
Q3 2019

Nov 12, 2019

SELL
$62.51 - $69.0 $697,611 - $770,040
-11,160 Closed
0 $0
Q2 2019

Aug 09, 2019

BUY
$61.87 - $69.38 $47,639 - $53,422
770 Added 7.41%
11,160 $707,000
Q1 2019

May 02, 2019

SELL
$62.53 - $70.05 $130,187 - $145,844
-2,082 Reduced 16.69%
10,390 $675,000
Q4 2018

Feb 06, 2019

BUY
$60.54 - $79.0 $171,812 - $224,202
2,838 Added 29.46%
12,472 $780,000
Q3 2018

Oct 23, 2018

SELL
$71.28 - $78.92 $19,103 - $21,150
-268 Reduced 2.71%
9,634 $744,000
Q2 2018

Jul 31, 2018

BUY
$64.88 - $75.68 $17,582 - $20,509
271 Added 2.81%
9,902 $701,000
Q1 2018

Apr 27, 2018

BUY
$72.84 - $88.8 $102,704 - $125,208
1,410 Added 17.15%
9,631 $726,000
Q4 2017

Feb 02, 2018

BUY
$71.15 - $83.52 $584,924 - $686,617
8,221
8,221 $589,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Telemus Capital, LLC Portfolio

Follow Telemus Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemus Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Telemus Capital, LLC with notifications on news.